Not intended for UK-based media

– Results from two studies of BAVENCIO® to be featured in ASCO press briefing

– Primary efficacy, biomarker and HRQoL analyses for tepotinib†, the first MET inhibitor to have received a regulatory approval for NSCLC with MET gene alterations

– Two-year follow-up for first-in-class bifunctional immunotherapy bintrafusp alfa‡ targeting TGF-β/PD-L1, in second-line NSCLC

ROCKLAND, Massachusetts, May 13, 2020 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced data for its innovative investigational agents and investigational uses of marketed medicines to be presented at the American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program, to be held virtually from May 29-31.

This year, ASCO will be highlighting—during its embargoed presscast on Tuesday, May 26 and at the plenary session on Sunday,